Chapter 188 - Pediatric vascular tumors Flashcards

1
Q

Types of pediatric vascular tumor

A

1) infantile hemangioma 2) congenital hemangioma 3) kaposiform hemangioendothelioma 4) pyogenic granuloma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Pediatric vascular tumor that can also be seen at any age

A

Pyogenic granuloma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Pediatric vascular tumour that’s considered intermediate and not fully benign

A

KHE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Differentiating vascular tumour from malformation

A

Tumours have proliferative endothelium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Infantile hemangioma cell type

A

Progenitor cells that are supposed to develop into blood vessels Multipotent hemangioma-derived stem cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Likely triggers of infantile hemangioma

A

hypoxia –> endothelial proliferation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Natural course of infantile hemangioma

A

Involute before age 4 tumour replaced by fat cells also derived from same stem cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Factors associated with infantile hemangioma

A

1) caucasian 2) premature low birth weight 3) female

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Most common location of lesions in infantile hemangioma

A

1) head & neck 2) trunk 3) extremity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Infantile hemangioma that are solitary lesions (rate)

A

80%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Appearance of infantile hemangioma tumour

A

if superficial dermis = bright red if deeper = bluish or normal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Chance of visceral hemangioma if > 5 cutaneous

A

16%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Most common visceral hemangioma location

A

liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Infantile hemangioma course

A

Growth - birth to 9 month; first 8 weeks rapid

Age 5 - 80% volume growth

Involution 1-4 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Disease associated with diffuse infantile hemangioma

A

1) replace liver parenchyma –> massive hepatomegaly
2) IVC compression
3) hypothyroidism (from deiodinase inactivation of thyroid hormone)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Hypothyroidism complication in children

A

Mental retardation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Segmental midline lumbosacral region infantile hemangioma associated with

A

33% spinal anomaly

1) tethered cord
2) lipoma
3) intraspinal hemangioma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Lower body infantile hemangioma associated with

A

LUMBAR

1) urogenital anomalies or ulceration
2) myelopathy
3) bone deformities
4) anorectal malformation
5) arterial and renal anomalies

mostly girls

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Segmental plaquelike infantile hemangioma of the face associated with

A

PHACES syndrome

1) posterior fossa brain malformation (72%)
2) hemangioma
3) arterial anomalies
4) coarctation of aorta and cardiac defects
5) eye abnormalities
6) sternal clefting or supraumbilical raphe

Mostly female

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Risk of PHACE syndrome in all infantile hemangioma

A

3%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Congenital hemangioma differentiate from infantile hemangioma

A

1) no post-natal growth
2) solitary usually 2-20 cm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Classic lesion of congenital hemangioma

A

1) red violaceous color
2) course telangiectasia
3) central pallor
4) peripheral pale halo

24
Q

Congenital hemangioma distribution in body

A

mostly in extremity

25
Gender distribution of congenital hemangioma
equal sex distribution
26
Classification of congenital hemangioma based on involution
1) rapidly involuting 2) partially involuting 3) non-involuting
27
Rapid involuting congenital hemangioma time frame for involution
Birth and most gone by 7-14 months
28
Skin appearance after involution of congenital hemangioma
1) atrophic skin 2) lack underlying subcutaneous adipose tissue (unlike IH)
29
Staining marker for infantile hemangioma
GLUT 1
30
Noninvoluting congenital hemangioma typical location
Head/neck 43% Extremity 38% torso 19%
31
Large rapidly involuting congenital hemangioma can cause
thrombocytopenia
32
Characteristic of a kaposiform hemangioendothelioma
1) \> 5cm in diameter +/- hair 2) 60% in neonatal and 90% by infancy 3) locally invasive but not metastatic 4) profound thrombocytopenia (Kasabach-Merritt) 5) reddish purple with ill-defined border
33
Epidemiology of kaposiform hemangioendothelioma
Equal gender distribution 1/100000
34
Distribution of kaposiform hemangioendothelioma
Head/neck 40% Truck/extremity 30%
35
Pyogenic granuloma characteristic
1) lobular capillary hemangioma 2) solitary red papule 6.5 mm 3) rapid growth with stalk 4) bleeds and ulcerates
36
Epidemiology of pyogenic granuloma
Male:female 2:1 mean age onset 7 years less likely at older ages
37
Location of pyogenic granuloma in the skin
90% cutaneous 12% mucous membrane
38
Causes of pyogenic granuloma
1) trauma 2) insect bite 3) viral infection 4) dermatologic disorder
39
Distribution of pyogenic granuloma in body
Head/neck 62% trunk 19% UE 13% LE 5%
40
Ultrasound of infantile hemangioma
1) well-circumscribed hypervascular mass 2) low resistance arterial waveform 3) venous drainage
41
MRI of infantile hemangioma in proliferative phase
1) parenchymal mass with dilated vessels and signal void 2) isointense on T1 3) hyperintense on T2 4) enhances homogeneously after admin of contrast
42
MRI of involuting infantile hemangioma
1) lobular with adipose tissue and less vessels 2) signal void or enhancement
43
Microscopic characteristics of infantile hemangioma in proliferative phase
1) tightly packed capillaries 2) plump endothelial cells 3) minimal intervascular stroma
44
Microscopic characteristics of infantile hemangioma in involution stage
1) reduced capillaries 2) increased stroma 3) increased fibrofatty tissue
45
MRI findings on KHE
1) infiltrative lesions 2) hypertense on T2 3) enhances with contrast 4) subcutaneous stranding 5) ill-defined boarders 6) prominent vessels with hemosiderin (signal voids)
46
Histopathology of KHE
1) lobules of spindled lymphatic endothelial cells 2) glomeruloid appearance 3) vessels with thrombi and hemosiderin 4) tumor immuno stain for lymphatic markers D240 and PROX1
47
Microscopic characteristics of pyogenic granuloma
1) exophytic mass with narrow stalk 2) normal number of mast cells (not like IH) 3) immature capillaries interspersed with fibroblastic tissue superficially 4) proliferating capillaries in lobular pattern deep
48
Rate of skin ulceration in IH
16%
49
Treatment of IH
1) conservative 2) topical antibiotic and vaseline 3) topical lidocaine 4) topical corticosteroid (clobestasol 5) timolol application 6) Propranolol if not improving (stops 90% of tumor growth)
50
Contraindication to systemic beta blocker for treating IH
1) reactive airway disease 2) congenital heart disease 3) glucose abnormalities
51
Systemic drugs for IH
1) beta blocker 2) steroid 3) interferon or vincristine (high side effect like spastic diplegia)
52
Surgical treatment for IH
1) embolization 2) pulsed dye laser therapy 3) excision of lesion
53
Managing of congenital hemangioma
1) self limiting if rapidly involuting 2) surgical resection if non-involuting
54
Kasabach-Merritt phenomenon
Profound thrombocytopenia \< 25 consumptive coagulopathy life threatening in 12-24% of the time
55
Goals of treating Kaposiform Hemangioendothelioma
1) prevent complication of Kasabach-Merritt 2) minimize fibrosis 3) reduce chronic pain 4) reduce stiffness and contractures
56
Treatment for Kasabach-Merritt
1) corticosteroid (10% effective) 2) vincristine (90%) 3) interferon (50%)
57